Expertise in
16
conditions

Dr. Mark A. Miller

Sinai Hospital Of Baltimore, Inc
Baltimore, MD
Expertise in
16
conditions
Specialties:Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Offers Telehealth
Expertise in
16
conditions
OverviewInsuranceLocationsClinical Research

Overview

Mark Miller is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Baltimore, Maryland. Dr. Miller is highly rated in 16 conditions, according to our data. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Malignant Mixed Mullerian Tumor, and Salpingo-Oophorectomy.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in PA
Hospital Affiliations
Northwest Hospital Center
Sinai Hospital Of Baltimore
Upmc Pinnacle Hospitals
Languages Spoken
English
Gender
Male

Insurance

MediFind strives to display the most accurate insurance information for every doctor. Please contact your provider to confirm if they accept your insurance.

Dr. Mark A. Miller accepts the following insurance:

  •  Cigna
  •  Highmark
  •  Humana

Locations

SINAI HOSPITAL OF BALTIMORE, INC
2411 W Belvedere Ave, 206 Sinai Gynecologic Oncol, Baltimore, MD 21215
410-578-9030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Active_not_recruiting
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Expertise in
27
conditions
Dr. Rebecca L. Stone
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
27
conditions
Dr. Rebecca L. Stone
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 5.4 mi
Languages Spoken English

Rebecca Stone is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Stone is highly rated in 27 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy.

Expertise in
34
conditions
Dr. Charles R. Boice
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
34
conditions
Dr. Charles R. Boice
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Medstar Medical Group Ii LLC

9000 Franklin Square Dr, 
Baltimore, MD 
 9.8 mi
Languages Spoken English

Charles Boice is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Boice is highly rated in 34 conditions, according to our data. His top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Malignant Mixed Mullerian Tumor, Salpingo-Oophorectomy, and Oophorectomy.

Expertise in
40
conditions
Dr. Teresa P. Diaz-Montes
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
40
conditions
Dr. Teresa P. Diaz-Montes
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

St Paul Place Specialists Inc

7602 Belair Rd, 
Baltimore, MD 
 7.7 mi
Languages Spoken English

Teresa Diaz-Montes is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Diaz-Montes is highly rated in 40 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Ovarian Carcinosarcoma, Hysterectomy, and Ureteroscopy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile